Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the ...

Tune Therapeutics，一家专注于表观遗传编辑技术的美国研发商，近日完成了B轮融资。本轮融资由Hevolution、Regeneron Ventures、Yosemite和恩颐投资等多家知名投资机构共同参与。

Tune Therapeutics’ co-founders, from left: Akira Matsuno, chief financial officer; Charles Gersbach; and Fyodor Urnov, who also serves on the startup’s scientific advisory board. (Tune Photos ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...